Charité - Universitätsmedizin Berlin

Psychosocial distress and utilization of professional psychological care in cancer patients: An observational study in National Comprehensive Cancer Centers (CCCs) in Germany. (2018) Weis J, Hoenig K, Bergelt C, Faller HH, Brechtel A, Hornemann B, Stein B, et al. Journal article Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex (2018) Brakemeier S, Vogt L, Adams LC, Zukunft B, Diederichs G, Hamm B, Budde K, et al. Journal article Current and Emerging Preclinical Approaches for Imaging-Based Characterization of Atherosclerosis (2018) Vigne J, Thackeray J, Essers J, Makowski M, Varasteh Z, Curaj A, Karlas A, et al. Journal article, Review article In vivo time-harmonic ultrasound elastography of the human brain detects acute cerebral stiffness changes induced by intracranial pressure variations (2018) Tzschaetzsch H, Kreft B, Schrank F, Bergs J, Braun J, Sack I Journal article International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management (2018) Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, Bauer JM, et al. Journal article Dosage and composition of bioactive glasses differentially regulate angiogenic and osteogenic response of human MSCs. (2018) Qazi TH, Berkmann JC, Schoon J, Geiler S, Duda GN, Boccaccini AR, Lippens E Journal article Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) Middeke JM, Rollig C, Kramer M, Kramer A, Bochtler T, Scholl S, Hochhaus A, et al. Conference contribution EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) Stasik S, Middeke JM, Kraemer M, Rollig C, Kramer A, Scholl S, Hochhaus A, et al. Conference contribution Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018) Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, et al. Conference contribution MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study (2018) Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M, et al. Conference contribution